This is a non-randomized, open-label, fixed sequence study to be conducted at multiple study centers.
The study will consist of 2 parts:
Part A of the study will comprise of:
* Screening period
* Treatment period: The treatment period will comprise of Cycles 1, 2 and 3 where the participants will receive AZD5335 along with itraconazole
* Follow-up visit (not applicable for participants involved in Part B)
Part B of the study will comprise of:
* Treatment period: Cycle 4 and onwards
* Safety Follow-up period
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participants with Platinum-resistant, relapsed, high- grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer and: (a) have received at least 1 prior line of platinum-containing chemotherapy and have progressed on or within 6 months after the date of the last dose of platinum; (b) must have received prior bevacizumab and/or Poly (ADP-ribose) polymerase (PARP) inhibitors according to local guidelines, unless ineligible.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
You may not be if
Spinal cord compression or a history of leptomeningeal carcinomatosis.
Unresolved toxicities of Grade ≥ 2 (National Cancer Institute-Common Terminology Criteria for Adverse Events v5.0) from prior therapy.
History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
Uncontrolled intercurrent illness within 12 months prior to screening.
Any other contraindication for receiving itraconazole according to the prescribing information and the Investigator.